NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
Diagnostics Assessment Programme

Faecal calprotectin diagnostic tests for identifying inflammatory bowel disease

Registered stakeholder list

07 December 2012

Manufacturer(s)
- Alpha Laboratories
- Biohit Healthcare
- Buhlmann Laboratories
- Calpro
- Immundiagnostik AG
- Preventis GmbH
- ThermoFisher Scientific ImmunoDiagnostics Division

General, Professional/Patient carer groups
- Abbott
- Brighton and Sussex University Hospitals
- Crohn’s and Colitis UK
- Darlington Memorial and Bishop Auckland Hospitals
- Department of Health
- Epsom & St. Helier NHS Trust
- Ferring Pharmaceuticals Ltd
- Firefly Scientific Ltd
- IBS Network
- King’s College Hospital NHS Foundation Trust
- Leeds General Infirmary
- Launch Diagnostics
- NHS Technology Adoption Centre
- Orchard Medical Centre
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Wolverhampton NHS Trust
- Sherwood Forest Hospitals NHS Foundation Trust
- St. George’s Hospital and Medical School
- St. George’s Medical Centre, New Brighton
- St. Mark’s Hospital, Harrow, London
- Stockport Primary Care Centre
- UK NEQAS (Birmingham Quality)
- Wolverhampton Hospital

Definition:

Registered stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the
results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.